ADIL Adial Pharmaceuticals, Inc
$5.05▲ +36.12%
Healthcare
Other
After hours
$5.07▲ +0.37%
Oct 28, 6:36 PM ET
Volume 83.1K
Avg Volume (10D) 20.9K
Key Metrics & Fundamentals
Market Cap
$13.26M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.31 - 9.25
% vs 50 MA
6.36%
% vs 200 MA
55.96%
RSI-14
62.8
MACD Histogram
+0.1500
Beta (1Y vs SPY)
0.88
Free Cash Flow
-$6.36M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$54.25M
COGS
–
Operating Exp
$52.03M
Operating Income
-$52.03M
EBIT
-$52.03M
Pretax Income
-$51.99M
Net Income
-$51.99M
EPS (Diluted)
-11.25
Price & Volume History
Loading chart…
Recent News
Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
GlobeNewswire · Oct 28, 2026 4:02 PM ET
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
GlobeNewswire · Oct 26, 2026 8:00 AM ET
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
GlobeNewswire · Oct 16, 2026 7:00 AM ET
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 30, 2026 5:46 PM ET
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Aug 25, 2026 4:05 PM ET
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
GlobeNewswire · Aug 17, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ADIL's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.